Saniona to present at three upcoming investor conferences

Saniona to present at three upcoming investor conferences




Saniona to present at three upcoming investor conferences

PRESS RELEASE

January 7, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will present in the following three upcoming virtual investor conferences:

10th Annual LifeSci Partners Corporate Access Event
Date: Thursday, January 7, 2021
Time: 11:30 a.m. Eastern Time
Presentation and 1×1 Meetings
Webcast Link: https://wsw.com/webcast/lifesci/sanion.st/2860611

Biotech Showcase
Date: Monday, January 11 – Friday, January 15, 2021
Time: On demand
Presentation and 1×1 Meetings
Webcast Link: https://informaconnect.com/biotech-showcase/digital-experience/

BIO CEO and Investor Digital Conference
Date: Tuesday, February 16 – Thursday, February 18, 2021
Time: On demand
Presentation and 1×1 Meetings
Webcast Link: https://www.bio.org/events/bio-ceo-investor-digital-conference/sessions?sessionTypes=25671   

As available, these events will be made accessible and archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227.
Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on January 7, 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment